Patients with diabetic macular edema experienced visual acuity gains and reduced central subfield thickness after 2 years of treatment with Beovu, according to a press release from Novartis.
Week 100 results of the phase 3 KESTREL study confirmed previous 1-year results and showed Beovu (brolucizumab) was beneficial and safe in patients with visual impairment due to DME.
The study compared the safety and efficacy of brolucizumab and Eylea (aflibercept, Regeneron) in patients with DME. Patients in the brolucizumab arm were treated every 6 weeks for a total of five doses, (Read more...)